المؤلفون: Barry L. Sharaf, William J. Rogers, J. Mark Haugland, Marc J. Schweiger, Richard C. Becker, Eugene Braunwald, Jeffrey L. Anderson, Neal S. Kleiman, Timothy D. Henry, Christopher P. Cannon, David O. Williams, Susan J. Edwards, Carolyn H. McCabe, Hiltrud S. Mueller, Robert S. Gibson

المصدر: Journal of the American College of Cardiology. 23(5):993-1003

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Hirudin Therapy, medicine.drug_class, medicine.medical_treatment, Hirudin, Myocardial Infarction, Pilot Projects, Coronary Angiography, Fibrinolytic Agents, Internal medicine, medicine, Humans, Thrombolytic Therapy, Myocardial infarction, Vascular Patency, Adjuvants, Pharmaceutic, Aged, Aspirin, Dose-Response Relationship, Drug, business.industry, T-plasminogen activator, Heparin, Anticoagulant, Thrombolysis, Hirudins, Middle Aged, medicine.disease, Recombinant Proteins, Survival Rate, Treatment Outcome, Direct thrombin inhibitor, Tissue Plasminogen Activator, Cardiology, Female, Partial Thromboplastin Time, business, Cardiology and Cardiovascular Medicine, TIMI, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50f1b4574ec20f6e9660778ed5c594b8